Glaukos Q2 2026 Sales Surge 50% on iDose TR and Epioxa as 85% Gross Margin Drives Guidance Raise

The Quick Take

• Glaukos Q2 2026 sales rose 50% year-over-year driven by commercial ramp of iDose TR sustained-release implant and Epioxa
• Gross margins expanded to 85% as premium ophthalmic surgical device mix shift benefits profitability substantially
• Management raised full-year 2026 guidance after the strong Q2 performance, citing second J-code reimbursement win

Glaukos's 50% Q2 sales jump represents one of the fastest growth rates among commercial-stage medical device companies, driven by the market adoption of two next-generation ophthalmic surgery products — iDose TR, a sustained-release glaucoma implant, and Epioxa, a corneal cross-linking platform. The 85% gross margin profile is exceptional even by medical device sector standards, reflecting the premium pricing power that proprietary surgical implant platforms command when paired with successful Medicare reimbursement codes. The second J-code referenced in Seeking Alpha's coverage signals successful Medicare reimbursement coding for a new procedure, which dramatically expands commercial access for hospital and outpatient surgery centers.

An 85% gross margin at 50% revenue growth creates an exceptional financial leverage profile — incremental revenue flows through to operating income at high rates as fixed costs are absorbed. For Glaukos shareholders, the guidance raise signals management has visibility into the commercial pipeline and is confident in the sustainability of the growth trajectory. Peers in the MEMS-based glaucoma treatment space — Iridex and Alcon — face competitive pressure if Glaukos's iDose TR expands its Medicare-covered indication, creating a broader addressable market for its premium pricing model.

The J-code expansion is the pivotal forward signal for Glaukos — a second successful reimbursement code means procedures are now reimbursable for a wider patient category, which directly expands the commercial addressable market without requiring additional clinical trials. Track Medicare reimbursement rate publication, typically Q4 for the following year, for indications of procedural economics. The key risk is whether Epioxa's growth trajectory sustains — corneal cross-linking is a competitive market with multiple entrants, and if average selling price erosion occurs, the 85% gross margin profile could compress from its current exceptional level.

Synthesized from 1 source.